Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis

Harindra Rajasekeran; Yuliya Lytvyn; David Z I Cherney

doi:10.1016/j.kint.2015.12.038

Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis

Kidney Int. 2016 Mar;89(3):524-6. doi: 10.1016/j.kint.2015.12.038.

Authors

Harindra Rajasekeran¹, Yuliya Lytvyn², David Z I Cherney³

Affiliations

¹ Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
² Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
³ Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: david.cherney@uhn.ca.

PMID: 26880444
DOI: 10.1016/j.kint.2015.12.038

Abstract

Inhibition of sodium-glucose cotransporter 2 causes both glycosuria and natriuresis, leading to reductions in hyperglycemia, body weight, blood pressure, and proteinuria. The recently published EMPA-REG OUTCOME study demonstrated significant cardiovascular and mortality benefits of sodium-glucose cotransporter 2 inhibition with empagliflozin in patients with type 2 diabetes and established cardiovascular disease, and may suggest a broader role for sodium-glucose cotransporter 2 inhibition in patients with heart failure.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Benzhydryl Compounds / adverse effects
Benzhydryl Compounds / therapeutic use*
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / mortality
Glucosides / adverse effects
Glucosides / therapeutic use*
Heart Failure / etiology
Heart Failure / mortality
Heart Failure / prevention & control*
Humans
Hypoglycemic Agents / therapeutic use*
Natriuresis / drug effects*
Protective Factors
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors*
Treatment Outcome

Substances

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin